Ways to minimize adverse drug reactions: Individualized doses and common sense are key

Postgraduate Medicine

Volumn 106, Issue 3, 1999, Pages 163-172

  Cohen, Jay S ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; AMLODIPINE BESYLATE; ATENOLOL; ATORVASTATIN; CAPTOPRIL; CLONIDINE; DICLOFENAC; ENALAPRIL MALEATE; FEXOFENADINE; FLUOXETINE; FLURAZEPAM; HYDROCHLOROTHIAZIDE; IBUPROFEN; METOPROLOL TARTRATE; MEVINOLIN; MISOPROSTOL; OMEPRAZOLE; ONDANSETRON; PRAVASTATIN; RANITIDINE; SILDENAFIL; SIMVASTATIN; TERFENADINE; TRAZODONE; ZOLPIDEM; ZOLPIDEM TARTRATE;

DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG MONITORING; DRUG RESPONSE; HIGH RISK PATIENT; HUMAN; PRESCRIPTION; REVIEW; SIDE EFFECT;

EID: 0032886742     PISSN: 00325481     EISSN: None     Source Type: Journal    
DOI: 10.3810/pgm.1999.09.688     Document Type: Review

References (29)

1. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 1998;279(15):1200-5
2. American Medical Association. Drug response variation and dosing information. In: Drug evaluations annual 1993. Philadephia: Saunders, 1993:chap 2
3. Clark WG, Brater DC, Johnson AR. Pharmacogenetics: the individual response to drugs. In: Goth A. Medical pharmacology. 12th ed. St Louis: Mosby, 1988: chap 6
4. Wernicke JF, Dunlop SR, Dornseif BE, et al. Low-dose fluoxetine therapy for depression. Psychopharmacol Bull 1988; 24(1):183-8
5. Louie AK, Lewis TB, Lannon RA. Use of low-dose fluoxetine in major depression and panic disorder. J Clin Psychiatry 1993; 54(11):435-8
6. Pies RW. Dose-related sensory distortions with zolpidem. (Letter) J Clin Psychiatry 1995;56(1):35-6
7. Merlotti L, Roehrs T, Koshorek G, et al. The dose effects of zolpidem on the sleep of healthy normals. J Clin Psychopharmacol 1989;9(1):9-14
8. Boolell M, Gepi-Attee S, Gingell JC, et al. Sildenafil, a novel effective oral therapy for male erectile dysfunction. Br J Urol 1996;78(2):257-61
9. Brandon ML, Weiner M. Clinical studies of terfenadine in seasonal allergic rhinitis. Arzneimittelforschung 1982;32(9a):1204-5
10. Food and Drug Administration. Post-marketing safety of sildenafil citrate (Viagra). Food and Drug Administration Web site.
11. Goldstein I, Lue TF, Padma-Nathan H, et al, for the Sildenafil Study Group. Oral sildenafil in the treatment of erectile dysfunction. N Engl J Med 1998; 338(20):397-404
12. Cohen JS, Insel PA. The Physicians' Desk Reference: problems and possible improvements. Arch Intern Med 1996; 156(13):1375-80
13. Durrigl T, Vitaus M, Pucar I, et al. Diclofenac sodium (Voltaren): results of a multi-centre comparative trial in adult-onset rheumatoid arthritis. J Int Med Res 1975;3(3):139-44
14. Salkind MR, Silverstone T. A clinical and psychometric evaluation of fturazepam. Br J Clin Pharmacol 1975;2(3):223-6
15. The Joint National Committee. The fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V). Arch Intern Med 1993;153(2):154-83
16. McEvoy GK, ed. American Hospital Formulary Service, Drug Information 1997. Bethesda: American Society of Hospital Pharmacists, 1997
17. Rubinstein A, Lurie Y, Groskop I, et al. Cholesterol-lowering effects of a 10 mg daily dose of lovastatin in patients with initial total cholesterol levels 200 to 240 mg/dl (5.18 to 6.21 mmol/liter). Am J Cardiol 1991;68(11):1123-6
18. Cohen MM, Clark L, Armstrong L, et al. Reduction of aspirin-induced fecal blood loss with low-dose misoprostol tablets in man. Dig Dis Sci 1985;30(7):605-11
19. Lauritsen K, Andersen BN, Havelund T, et al. Effect of 10 mg and 20 mg omeprazole daily on duodenal ulcer: double-blind comparative trial. Aliment Pharmacol Ther 1989;3(1):59-67
20. Gibian T. Rational drug therapy in the elderly or how not to poison your elderly patients. Aust Fam Physician 1992;21(12): 1755-60
21. Everitt DE, Avorn J, Baker MW. Clinical decision-making in the evaluation and treatment of insomnia. Am J Med 1990;89(3):357-62
22. Dutch study attempts to quantify sexual dysfunction profiles among SSRIs. Primary Psychiat 1997;4(7):22-3
23. Nawrocki J, Weiss S, Davidson MH, et al. Reduction in LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arterioscler Thromb Vasc Biol 1995;15(5):678-82
24. Chalmers TM. Clinical experience with ibuprofen in the treatment of rheumatoid arthritis. Ann Rheum Dis 1969;28(5): 513-7
25. Beck TM, Ciociola AA, Jones SE, et al. Efficacy of oral ondansetron in the prevention of emesis in outpatients receiving cyclophosphamide-based chemotherapy. Ann Intern Med 1993;118(6):407-13
26. Jones PH, Farmer JA, Cressman MD, et al. Once-daily pravastatin in patients with primary hypercholesterolemia: a dose-response study. Clin Cardiol 1991;14(2): 146-51
27. Physicians' Desk Reference, 53d ed. Montvale, NJ: Medical Economics, 1999
28. Saku K, Sasaki J, Arakawa K. Low-dose effect of simvastatin (MK-733) on serum lipids, lipoproteins, and apolipoproteins in patients with hypercholesterolemia. Clin Ther 1989;11(2):247-57
29. Schatzberg AF, Dessain E, O'Neil P, et al. Recent studies on selective serotonergic antidepressants: trazodone, fluoxetine, and fluvoxamine. J Clin Psychopharmacol 1987;7(6 Suppl):44-9S